Letter Expression of Glucagon-Like Peptide-1 Receptor in Papillary Thyroid Carcinoma and Its Clinicopathologic Significance

Glucagon-like peptide (GLP-1)-based therapy is a method of lowering blood glucose levels [1]. This glycemic control strat-egy, which increases insulin secretion in a glucose-dependent manner by regulating GLP-1 receptor (GLP-1R) agonist and dipeptidyl peptidase-4 inhibitor levels artificially, induces less hypoglycemia and reduces weight gain (rather than stimulating weight loss) compared with other treatments [2]. Despite such benefits, the mechanism of action of GPL-1 is not understood completely. Interestingly, previous studies have revealed that GLP-1 plays important roles in cellular processes such as pro-liferation and apoptosis; for example, GLP-1 stimulates the proliferation of pancreatic β-cells [3]. Recently, Jung and Kwon [4] reported that GLP-1R was ex-pressed occasionally in papillary thyroid cancer (PTC) tissues. Furthermore, GLP-1R expression in PTC was associated wit